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A B S T R A C T
Background
Asymptomatic bacteriuria, defined as bacteriuria without signs or symptoms of urinary tract infection (UTI), occurs in 17% to 51%
of kidney transplant recipients and is thought to increase the risk for a subsequent UTI. No consensus exists on the role of antibiotics
for asymptomatic bacteriuria in kidney transplantation.
Objectives
To assess the benefits and harms of treating asymptomatic bacteriuria in kidney transplant recipients with antimicrobial agents to
prevent symptomatic UTI, all-cause mortality and the indirect effects of UTI (acute rejection, graft loss, worsening of graft function).
Search methods
We searched the Cochrane Kidney and Transplant Register of Studies up to 1 September 2017 through contact with the Information
Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE,
and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal, and ClinicalTrials.gov.
Selection criteria
All randomised controlled trials (RCTs) and quasi-RCTs in any language assessing treatment of asymptomatic bacteriuria in kidney
transplant recipients at any time-point after transplantation.
Data collection and analysis
Two authors independently determined study eligibility, assessed quality and extracted data. Primary outcomes were incidence of
symptomatic UTI and incidence of antimicrobial resistance. Other outcomes included incidences of all-cause mortality, graft loss, graft
rejection, graft function, hospitalisation for UTI, adverse reactions to antimicrobial agents and relapse or persistence of asymptomatic
bacteriuria. We expressed dichotomous outcomes as absolute risk difference (RD) or risk ratio (RR) with 95% confidence intervals
(CI) and continuous data as mean differences (MD) with 95% CI. Data were pooled using the random effects model.
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Main results
We included two studies (212 participants) comparing antibiotics versus no treatment, and identified three on-going studies. Overall,
incidence of symptomatic UTI varied between 19% and 31% in the groups not treated for asymptomatic bacteriuria. Antibiotic
treatment had uncertain effects on preventing symptomatic UTI (2 studies, 200 participants: RR 0.86, 95% CI 0.51 to 1.45). Risk
for selecting multidrug-resistant organisms was uncertain with antibiotic treatment (1 study, 112 participants: RR 1.21, 95% CI 0.60
to 2.41). Persistence of asymptomatic bacteriuria was high regardless of treatment. Antibiotics also have uncertain effects on other
important patient and graft outcomes, for instance on all-cause mortality (1 study, 112 participants: RR 2.23, 95% CI 0.21 to 23.86),
graft loss (1 study, 112 participants: RR 1.11, 95% CI 0.07 to 17.36), acute rejection (1 study, 112 participants: RR 0.93, 95% CI 0.44
to 1.97), hospitalisation for UTI (1 study, 112 participants: RR 0.74, 95% CI 0.13 to 4.27), graft function (2 studies, 200 participants,
MD in serum creatinine concentration -0.06 mg/dL, 95% CI -0.19 to 0.08) and adverse reactions (1 study, 112 participants: no severe
adverse event attributable to the antibiotic treatment). Evidence quality was low for all outcomes.
Authors’ conclusions
Currently, there is insufficient evidence to support routinely treating kidney transplant recipients with antibiotics in case of asymptomatic
bacteriuria after transplantation, but data are scarce. Further studies assessing routine antibiotic treatment would inform practice and
we await the results of three ongoing randomised studies, which may help resolve existing uncertainties.
P L A I N L A N G U A G E S U M M A R Y
Antibiotics for bacterial infection in the urine in kidney transplant recipients when there are no symptoms
What is the issue?
Bacteria in the urine in kidney transplant recipients when there are no symptoms of urine infection is called asymptomatic bacteriuria.
Up to one in two people with a kidney transplant will develop a bacterial infection of the urine (bacteriuria) at some point after
transplantation. Bacteriuria with symptoms like fever, chills, painful urination, abdominal pain and blood in urine is a urinary tract
infection (UTI). Bacteriuria often occurs without symptoms and it is frequently treated with antibiotics with the idea this might help
avoid subsequent UTI. Avoiding UTI might improve patient and transplant survival. However, it is unclear how many people with
asymptomatic bacteriuria go on to develop UTI symptoms; whether treatment with antibiotics truly avoids UTI; or whether treatment
when asymptomatic improves survival of both patient and kidney. Also, there can be downsides to taking antibiotics. Taking regular
antibiotics might mean that bacteria resistant to antibiotics are encouraged, and taking antibiotics might cause diarrhoea and other
adverse events. There are also antibiotic costs to consider. This review looked at whether treating with antibiotics is beneficial of harmful.
What did we do?
We searched the literature up to September 2017 and identified two studies (212 participants) that were evaluated in this review. These
studies compared antibiotics versus no treatment.
What did we find?
The bacterial infection of the urine often persisted, whether antibiotics were given or not. It was uncertain whether antibiotics prevented
symptomatic urinary infection or increased the risk of selecting bacteria resistant to antibiotics, because there were too few data and
several limitations in the included studies. Also, it was unclear whether the use of antibiotics in case of urinary infection without
symptoms reduced the risks of graft rejection, need for hospitalisation due to symptoms of urinary infection, or mortality, or whether
antibiotics improved the function of the kidney transplant. One study with 112 participants suggested there were no severe harmful
reactions caused by the antibiotic treatment, and non-severe adverse events appeared to be rare.
Conclusions
It is uncertain whether antibiotics are beneficial in kidney transplant recipients with bacteria in their urine but no symptoms. In one
study, participants were assigned to antibiotics or no therapy by a method that was not random (i.e. according to patients’ transplant
code). In both studies, participants knewwhich treatment theywere receiving (i.e. antibiotics or no therapy), whichmay have influenced
the results. Last, we had not enough data to estimate with precision some effects of antibiotics. More research is needed.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antibiotics versus no treatment for asymptomatic bacteriuria in kidney transplant recipients
Patient or population: adult kidney transplant recipients
Intervention: ant ibiot ics1
Comparison: no treatment1
Outcomes
(follow-up period)
Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Risk with no treatment Risk with antibiotics
Symptomatic UTI
Follow-up: 12 to 22 months
240 per 1,000 207 per 1 000
(123 to 349)
RR 0.86 (0.51 to 1.45) 200 2 (2 studies) Low 3
⊕⊕©©
Antim icrobial resistance
Mean follow-up: 16.9
months
203 per 1,000 245 per 1,000
(123 to 490)
RR 1.21 (0.60 to 2.41) 112 (1 study) Low 4
⊕⊕©©
All-cause mortality
Mean follow-up: 16.9
months
17 per 1,000 38 per 1,000
(4 to 404)
RR 2.23 (0.21, 23.86) 112 (1 study) Low 5
⊕⊕©©
Graf t loss
Mean follow-up: 16.9
months
17 per 1,000 19 per 1,000
(1 to 294)
RR 1.11 (0.07 to 17.36) 112 (1 study) Low 5
⊕⊕©©
Acute graf t reject ion
Mean follow-up: 16.9
months
203 per 1,000 189 per 1,000
(89 to 401)
RR 0.93 (0.44 to 1.97) 112 (1 study) Low 6
⊕⊕©©
Hospitalisat ion for UTI
Mean follow-up: 16.9
months
51 per 1,000 38 per 1,000
(7 to 217)
RR 0.74 (0.13 to 4.27) 112 (1 study) Low 5
⊕⊕©©
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Graf t funct ion (creat inine at
end of study)
Follow-up: 12 to 22 months
Mean serum creat inine in the treatment group was 0.06 mg/ dL lower (0.19 mg/ dL
lower to 0.08 mg/ dL higher) than the control group
200 2 (2 studies) Low 7,8
⊕⊕©©
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RD: risk dif f erence; RR: risk rat io; UTI: urinary tract infect ion
1 The two included studies compared ant ibiot ics versus no treatment, with choice of ant ibiot ics depending on ant im icrobial suscept ibility test ing results. As part icipants could
have had mult iple episodes of asymptomatic bacteriuria during the follow-up period, part icipants f rom the intervent ion group were retreated with ant ibiot ics if asymptomatic
bacteriuria recurred during the follow-up period in both studies. Durat ion of ant ibiot ics therapy ranged f rom 3 to 10 days for the f irst episode of asymptomatic bacteriuria
2 212 part icipants included but data provided for 200 part icipants
3 Neither study attempted to blind part icipants, personnel or data analysts. As symptoms of UTI are part ly subject ive, we ant icipated this would put the results at risk of being
biased in favour of ant ibiot ic treatment
4 Samples could be collected both in case of symptoms of UTI or as part of rout ine screening
5 The conf idence interval crosses the line of no ef fect but does not rule out a signif icant ef fect of ant ibiot ics on mortality and/ or graf t loss
6 No systematic graf t biopsy performed during the study follow-up. Not all episodes of allograf t reject ion were biopsy-proven
7 Graf t funct ion was evaluated using creat inine at end of study, despite dif f erent values between groups at t ime of inclusion. We were unable to pool the data for change in
graf t funct ion f rom baseline to end of study (data missing for one study)
8 No signif icant ef fect of ant ibiot ics on change in graf t funct ion f rom baseline to end of study in both studies
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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B A C K G R O U N D
Description of the condition
Asymptomatic bacteriuria is generally defined as bacteriuria with-
out signs or symptoms of urinary tract infection (UTI; e.g. dysuria,
frequency, suprapubic pain or fever). The Infectious Diseases So-
ciety of America (IDSA) defines bacteriuria in men as one bacterial
species isolated from a single, clean-catch voided urine specimen
in a quantitative count ≥ 105 colony forming units (CFU)/mL
(Nicolle 2005). In asymptomatic women, diagnosis of bacteriuria
requires a second urine specimen with isolation of the same bacte-
rial strain in a quantitative count ≥ 105 CFU/mL. If a urine sam-
ple is collected through catheterization, a single urine specimen
with isolation of a single bacterial species in a quantitative count
≥ 100 CFU/mL is enough to identify bacteriuria in women or
men.
Observational studies from the 1970s and 1980s reported high
incidences of asymptomatic bacteriuria in kidney transplant re-
cipients, especially in the first six months after transplantation
(Nicolle 2005). Many patients also developed symptomatic UTI
with subsequent ramifications for graft function (Tolkoff-Rubin
1982). This promptedmany clinicians to screen for asymptomatic
bacteriuria and treat with antibiotics on the presumption it would
reduce the incidence of symptomatic episodes and improve graft
and patient outcomes in the longer term (Abbott 2004).
The past two decades have seen several changes in the manage-
ment of transplant recipients including the introduction of routine
perioperative antibiotic prophylaxis, earlier removal of indwelling
urethral catheters, and long-term antibiotic prophylaxis for pre-
venting Pneumocystis jirovecii pneumonia and other opportunistic
infections (KDIGO 2009; Nicolle 2005). These interventions are
also expected to prevent UTI and asymptomatic bacteriuria.
At present, asymptomatic bacteriuria is estimated to occur in 17%
to 51% of kidney transplant recipients, estimates largely depend-
ing on definition of asymptomatic bacteriuria, follow-up period,
and frequency of urine sampling (El Amari 2011; Fiorante 2010;
Green 2013). The limited retrospective data available seem to in-
dicate that few asymptomatic episodes lead to symptomatic or
severe UTI, and that graft function is not affected (El Amari
2011;Green2013).Most transplant physicians still, however, treat
asymptomatic bacteriuria after transplantation. Reasons include
the possibility that denervation of the kidney graft and the use of
immunosuppressivemedicationsmask the clinical features ofUTI,
and the fear that kidney transplant recipients may be at higher risk
for developing severe infections (Parasuraman 2013).
Description of the intervention
Treatment of asymptomatic bacteriuria involves the detection of
bacteria in urine through routine processing of urine cultures.
Once diagnosis of asymptomatic bacteriuria has been established,
treatment with antibiotics may be started with the aim to prevent
progression to symptomatic UTI (e.g. acute graft pyelonephritis).
How the intervention might work
Antibiotics are given under the assumption they are effective in
improving individual patient outcomes by eliminating infection,
reducing recurrence and preventing long-term kidney damage.
Why it is important to do this review
Screening for and treatment of asymptomatic bacteriuria may be
beneficial if asymptomatic bacteriuria has negative effects that
could be reduced with antibiotics. There is consensus that the ben-
efits of screening and treatment outweigh the harms in patients
awaiting transurethral resectionof the prostate (Nicolle 2005;Zani
2011). In the general population though, the available data do not
support the use of antibiotics to treat asymptomatic bacteriuria. In
pregnantwomen, the routine screen-treat-policy for asymptomatic
bacteriuria has recently been called into question (Kazemier 2015;
Smaill 2015). In healthy, non-pregnant young women it may even
increase the risk of symptomatic UTI (Cai 2012).
No consensus exists on the role of antibiotics for asymptomatic
bacteriuria in kidney transplantation (Nicolle 2014a). The 2005
IDSA guidelines for the diagnosis and treatment of asymptomatic
bacteriuria in adults refrained from making a recommendation in
kidney transplant recipients for want of evidence (Nicolle 2005).
In 2013, the American Society of Transplantation Infectious Dis-
eases Community of Practice suggested not treating asymptomatic
bacteriuria that occurs beyond three months after kidney trans-
plantation, unless in case of an accompanying rise in serum creati-
nine (SCr) concentration (Parasuraman 2013). However, the au-
thors underlined that the recommendation was not based on ran-
domised controlled studies (RCTs) and that general adoption of
such a strategy could lead to over-treatment and selection of resis-
tant micro-organisms. Indeed, there is some concern that treating
kidney transplant recipients with asymptomatic bacteriuria with
antibiotics leads to selection of resistant strains (El Amari 2011).
Aside from the possible consequences for the individual, theremay
be ramifications for society at large (Goossens 2005). In addition,
treatment may have direct and very harmful side-effects (e.g. flu-
oroquinolone-induced Achilles tendon rupture), cause severe al-
lergic complications (Chang 2012) and promote Clostridium dif-
ficile-associated diarrhoea (Shah 2013).
O B J E C T I V E S
To assess the benefits and harms of treating asymptomatic bac-
teriuria in kidney transplant recipients with antimicrobial agents
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to prevent symptomatic UTI, all-cause mortality and the indirect
effects of UTI (acute rejection, graft loss, worsening of graft func-
tion).
M E T H O D S
Criteria for considering studies for this review
Types of studies
All RCTs and quasi-RCTs (RCTs in which allocation to treatment
was obtained by alternation, use of alternate medical records, date
of birth or other predictable methods) looking at treatment of
asymptomatic bacteriuria in kidney transplant recipients.
Types of participants
Inclusion criteria
• Adults and children with end-stage kidney disease, who are
recipients of a first or subsequent cadaveric or living donor
kidney transplant, including combined grafts (e.g. kidney-
pancreas).
• Asymptomatic bacteriuria defined according to the IDSA
definitions or as defined by the authors, at any time-point after
transplantation.
IDSA definition of asymptomatic bacteriuria:
• In men: a single, clean-catch voided urine specimen with
one bacterial species isolated in a quantitative count ≥ 105 CFU/
mL in the absence of symptoms or signs of UTI.
• In women: two consecutive voided urine specimens with
isolation of the same bacterial strain in quantitative counts ≥ 10
5 CFU/mL in the absence of symptoms or signs of UTI.
• A single catheterized urine specimen with one bacterial
species isolated in a quantitative count ≥ 100 CFU/mL
identifies bacteriuria in women or men.
Exclusion criteria
• Pregnant women, as antibiotic treatment of asymptomatic
bacteriuria in pregnancy effectively reduces the risk of
pyelonephritis in the mother and possibly reduces the chance a
baby will be born too early or have a low birthweight. This
question has been addressed in a Cochrane review (Smaill 2015).
• Transplant recipients awaiting transurethral resection of the
prostate or any other urologic procedure during which mucosal
bleeding is anticipated, as antibiotic treatment of asymptomatic
bacteriuria is recommended in this setting (Nicolle 2005).
Types of interventions
We included studies of any antibiotic medication and investigated
the following comparisons:
• Any antibiotic medication versus placebo or no treatment
• Any antibiotic medication versus any other antibiotic
medication
• Low dose versus high dose of the same antibiotic medication
• Short-course versus long-course antibiotic therapy
• Oral versus intravenous (IV) administration of the same or
different antibiotic medication.
Types of outcome measures
Primary outcomes
• Incidence of symptomatic UTI (isolation of a bacterial
species from a patient with signs or symptoms of UTI, i.e.
cystitis, pyelonephritis, prostatitis)
• Incidence of antimicrobial resistance (isolation of
multidrug-resistant bacteria, with multidrug-resistance being
defined as non-susceptibility to at least one agent in three or
more antimicrobial categories).
Secondary outcomes
• All-cause mortality
• Graft loss including death with a functioning graft
• Graft rejection (classified as clinically suspected and treated,
or biopsy proven)
• Graft function as measured by SCr concentration,
estimated or measured glomerular filtration rate
• Hospitalisation for UTI
• Adverse reactions to antimicrobial agents (i.e. allergic
reactions, toxicity)
• Relapse or persistent asymptomatic bacteriuria.
Relapsing and persistent asymptomatic bacteriuria were defined
as follows:
• Relapsing asymptomatic bacteriuria: recurrence of
asymptomatic bacteriuria after clearance of the initial isolate
• Persistent asymptomatic bacteriuria: persistence of an
organism similar to the initial isolate (same species with similar
antimicrobial-susceptibility profile).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Kidney and Transplant Register of
Studies up to 1 September 2017 through contact with the Infor-
mation Specialist using search terms relevant to this review. The
Register contains studies identified from the following sources.
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1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney and transplant-related journals
and the proceedings of major kidney and transplant conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney and
transplant journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov
Studies contained in the Register are identified through search
strategies for CENTRAL, MEDLINE, and EMBASE based on
the scope of Cochrane Kidney and Transplant. Details of these
strategies, as well as a list of handsearched journals, conference
proceedings and current awareness alerts, are available in the “Spe-
cialised Register” section of information about Cochrane Kidney
and Transplant.
See Appendix 1 for search terms used for this review.
Searching other resources
1. Reference lists of review articles, relevant studies and
clinical practice guidelines.
2. Letters seeking information about unpublished or
incomplete studies to investigators known to be involved in
previous studies.
Data collection and analysis
Selection of studies
The search strategy described was used to obtain titles and ab-
stracts of studies possibly relevant to the review. The titles and ab-
stracts were screened independently by two authors who discarded
studies that were not applicable. However, studies and reviews that
possibly included relevant data or information on studies were
retained initially. The same two authors independently assessed
retrieved abstracts, and if necessary the full text of these studies,
to determine which studies satisfied the inclusion criteria.
Data extraction and management
Data extraction was carried out independently by two authors us-
ing standard data extraction forms. Studies reported in non-En-
glish language journals were translated before assessment. Where
more than one publication of one study existed, reports were
grouped together and the publication with themost complete data
was used in the analyses. Where relevant outcomes were only pub-
lished in earlier versions these data were used.
Assessment of risk of bias in included studies
The following items were independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study?
◦ Participants and personnel (performance bias)
◦ Outcome assessors (detection bias)
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
Measures of treatment effect
For dichotomous outcomes (symptomatic UTI, death, graft loss,
allograft rejection, hospitalisation for UTI, adverse reactions to
antimicrobial agents, asymptomatic bacteriuria relapse and persis-
tence, antimicrobial resistance), results were expressed as absolute
risk difference (RD) or risk ratio (RR) with 95% confidence in-
tervals (CI). Where continuous scales of measurement are used to
assess the effects of treatment (graft function), themean difference
(MD) was used.
Unit of analysis issues
The unit of analysis within each study was the individual patient.
All the studies included used a simple parallel group design.
Dealing with missing data
Any further information required from the original author were
requested by written correspondence (e.g. emailing correspond-
ing author) and any relevant information obtained in this manner
were included in the review. Evaluation of important numerical
data such as screened, randomised patients as well as intention-to-
treat, as-treated and per-protocol population were carefully per-
formed. Attrition rates, for example drop-outs, losses to follow-
up and withdrawals were investigated. Issues of missing data and
imputation methods (e.g. last-observation-carried-forward) were
critically appraised (Higgins 2011).
Assessment of heterogeneity
We planned to assess the heterogeneity by visual inspection of the
forest plot. Heterogeneity was then analysed using a Chi2 test on
N-1 degrees of freedom, with an alpha of 0.05 used for statistical
significance and with the I2 test (Higgins 2003). A guide to the
interpretation of I2 values is as follows.
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• 0% to 40%: might not be important
• 30% to 60%: may represent moderate heterogeneity
• 50% to 90%: may represent substantial heterogeneity
• 75% to 100%: considerable heterogeneity.
The importance of the observed value of I2 depends on the mag-
nitude and direction of treatment effects and the strength of evi-
dence for heterogeneity (e.g. P-value from the Chi2 test, or a con-
fidence interval for I2) (Higgins 2011). Lack of data prevented
informative formal heterogeneity analysis.
Assessment of reporting biases
We planned to assess the possibility of publication bias for every
outcome studied, but there were too few studies to allow mean-
ingful evaluation.
Data synthesis
Data were pooled using the random-effects model but the fixed-
effectmodel was also used to ensure robustness of themodel chosen
and susceptibility to outliers.
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analysis to explore possible
sources of heterogeneity.
Heterogeneity amongparticipants could be related to age, sex, time
from transplantation to asymptomatic bacteriuria, and possible
presence of a ureteric stent. Heterogeneity in treatments could be
related to prior agent(s) used and the agent, dose and duration of
antibiotic therapy.
Heterogeneity among bacterial strains could be related to the fol-
lowing conditions:
• species involved (Escherichia coli versus other strains),
• degree of resistance (multidrug-resistant strains versus non-
multidrug-resistant, with multidrug-resistance being defined as
non-susceptibility to at least one agent in three or more
antimicrobial categories)
The paucity of data precluded us from assessing heterogeneity.
Sensitivity analysis
We planned to perform sensitivity analysis in order to examine
the stability of the results in relation to the quality of the included
studies. As only two studies with available results were included
in the review, it was not feasible to perform a sensitivity analysis
’Summary of findings’ tables
We presented the main results of the review in the ’Summary of
findings’ table. This table presents key information concerning
the quality of the evidence, the magnitude of the effects of the
interventions examined, and the sum of the available data for the
main outcomes (Schünemann 2011a). The ’Summary of findings’
table also includes an overall grading of the evidence related to
each of the main outcomes using the GRADE (Grades of Recom-
mendation, Assessment, Development and Evaluation) approach
(GRADE 2008). The GRADE approach defines the quality of
a body of evidence as the extent to which one can be confident
that an estimate of effect or association is close to the true quan-
tity of specific interest. The quality of a body of evidence involves
consideration of within-trial risk of bias (methodological quality),
directness of evidence, heterogeneity, precision of effect estimates
and risk of publication bias (Schünemann 2011b). We presented
the following outcomes in the ’Summary of findings’ table.
• Symptomatic UTI
• Antimicrobial resistance
• All-cause mortality
• Graft loss
• Acute graft rejection
• Hospitalisation for UTI
• Graft function
R E S U L T S
Description of studies
Results of the search
We identified 32 reports through electronic searches. We added
one additional report by contacting authors of an identified study
(Origuen 2016). We reviewed these 33 reports in detail and iden-
tified 24 studies. Two studies (six reports) were included and 19
studies (24 reports) were excluded. Three ongoing studies were
identified and will be assessed in a future update of this review
(NCT01771432; BiRT Study 2013; NCT02113774) (Figure 1).
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Figure 1. Study flow diagram.
Included studies
The two studies (212 participants enrolled, data provided for 200
participants) compared antibiotics versus no treatment, with the
choice of antibiotics depending on antimicrobial susceptibility
testing results (Moradi 2005; Origuen 2016). In both studies, par-
ticipants from the intervention group were retreated with antibi-
otics if asymptomatic bacteriuria recurred during the follow-up
period. In Moradi 2005, participants took oral antibiotics for 10
days; we were unable to obtain details regarding choice of antibi-
otics or dosing. In Origuen 2016, participants received antibiotics
for three to seven days during the first episode of asymptomatic
bacteriuria, and for two and six weeks during the second and sub-
sequent episodes. The choice of antibiotic, dosing and route of
administration were left to the discretion of the treating physician
(protocol not provided). In 94% of cases, participants took one of
eight different antibiotics orally; IV antibiotics were given when
considered appropriate by the treating physician.
Both studies exclusively enrolled adult kidney transplant recipi-
ents.
Moradi 2005 enrolled 100 participants with asymptomatic bac-
teriuria occurring at least one year after transplantation, who did
not have ureteral stents, indwelling urethral catheters and/or a Pro-
teus species isolated from the urine culture. Asymptomatic bacteri-
uria was defined as the joint presence of pyuria and bacteriuria in
urinalysis; a colony count greater than 100,000 CFU/mL of a sin-
gle organism after urine culture; and the absence of irritative void-
ing symptoms, fever, or chills. Specific strategies to obtain good
quality urine samples were not mentioned. Half the participants
were women (50/100), aged 45 ± 13 years. E. coli was the most
common isolate (65%, 57/88 episodes); there was no information
on the level of antimicrobial resistance regarding baseline episodes
of bacteriuria. The investigators reported outcomes up to 9 to 12
months after randomisation.
Origuen 2016 enrolled 112 outpatients with asymptomatic bac-
teriuria occurring at least two months after transplantation. They
excluded people with a simultaneous kidney-pancreas transplant,
a ureteral stent, an indwelling urethral catheter, pregnant women,
or people who had lost the graft during the first two months af-
ter transplantation. Also, patients who had at least one episode of
asymptomatic bacteriuria between the end of the second month
after transplantation and the trial screening were excluded (n =
30). Asymptomatic bacteriuria was defined according to IDSA
guidelines (Nicolle 2005) and dedicated nurses educated patients
in order to obtain good quality urine samples. Participants were
about 10 years older than in Moradi 2005 (mean age 54 ± 15
years), just under half were women (53/112; 47%). E. coli was the
most commonly isolated micro-organism (43% of episodes); there
was no information on the level of antimicrobial resistance regard-
ing baseline episodes of bacteriuria. Of the participants enrolled,
92% were within the first year after transplantation, with a me-
dian time from transplantation to study inclusion of 83 days. Out-
comes were recorded until two years after transplantation or until
acute pyelonephritis, graft loss or death occurred during the study
period. Median duration of follow-up was 16.9 months (range
0.43 to 22).
Both studies evaluated the incidences of symptomatic UTI and
persistent asymptomatic bacteriuria, as well as graft function
(Origuen 2016,Moradi 2005). Origuen and co-workers also eval-
uated the incidences of acute pyelonephritis (which was selected
as their primary outcome), lower UTI, hospital admission due
to UTI, antimicrobial resistance, C. difficile-associated diarrhoea,
acute allograft rejection, graft loss, adverse events and all-cause
mortality (Origuen 2016).
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Excluded studies
We excluded 19 studies. All studies enrolled kidney transplant
recipients but participants were included independently of the
presence or absence of asymptomatic bacteriuria. Nine studies
evaluated the effect of pre- or perioperative antimicrobial pro-
phylaxis (Castelao 1993; Cohen 1988; Ferreira 1990; Matteucci
1998; Robles 1990; Salehipour 2010; Salmela 1990; Townsend
1980; Wilms 1986), nine studies evaluated the role of antimicro-
bial prophylaxis of bacterial infection after transplantation (Fox
1990; Hibberd 1992; Khosroshahi 2006; Maddux 1989;Melchor
1996;Moyses-Neto 1997; NCT01820897; Tegzess 1986; Tolkoff
1982) and one study evaluated the safety of cotrimoxazole in kid-
ney transplant recipients treated with azathioprine (Hall 1974).
Risk of bias in included studies
See Characteristics of included studies, Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Origuen 2016 used a computer to generate the randomisation
sequence and consecutively numbered sealed envelopes to mask
the allocation such that we considered the risk of selection bias to
be low. Moradi 2005 used the transplantation code to determine
the allocation sequence, entailing a high risk of selection bias.
Blinding
Neither study attempted to blind participants, personnel or data
analysts. As symptoms of UTI are partly subjective, we anticipated
this would put the results at risk of being biased in favour of antibi-
otic treatment. Moreover, there were differences between groups
in how persistence of asymptomatic bacteriuria was determined
in Origuen 2016. In the antibiotics group, investigators asked the
participants to do a urinalysis two weeks after completing the an-
timicrobial therapy. In the control group, no systematic urinalysis
occurred at two weeks but subsequent cultures were used to eval-
uate this outcome.
Incomplete outcome data
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We considered both studies to be at high risk of attrition bias.
Moradi 2005 excluded 12/100 participants from the analysis after
loss to follow-up (11) or the occurrence of acute graft pyelonephri-
tis (1). Baseline characteristics and outcomes were only reported
for the remaining 88 participants. Origuen 2016 included all
112 participants into the intention-to-treat analyses. However,
little more than half reached the end of the two year study pe-
riod (54.5%, 61/112 patients). This is partly attributed to the
fact that participants were withdrawn after they developed acute
pyelonephritis (9) or graft loss (2), which could have biased results
for the other outcomes.
Selective reporting
Origuen 2016 had a registered protocol which was published on
Clinicaltrials.gov after the end of the recruitment period. That
said, the authors reported all expected outcomes related to both
benefits and harms and we considered the risk of reporting bias to
be low.Moradi 2005 failed to report outcomes such as incidence of
pyelonephritis, antimicrobial resistance, graft rejection and graft
loss, all-cause mortality, hospitalisation for UTI, and adverse re-
actions to antimicrobial agents. As such, we considered it at high
risk of reporting bias.
Other potential sources of bias
Moradi 2005 did not provide a specific definition of the term
“symptomatic UTI” and there were no details on the episodes of
symptomatic UTI. Attempts to contact the corresponding author
were unsuccessful. Because the incidence of symptomatic UTI was
one of our primary outcomes, we considered it at high risk of bias.
We considered the risk of sponsorship bias to be low due to the
nature of the research question.
Effects of interventions
See: Summary of findings for the main comparison Antibiotics
versus no treatment for asymptomatic bacteriuria in kidney
transplant recipients
Symptomatic UTI
Overall, incidence of symptomatic UTI varied between 19% and
31% in the groups not treated for asymptomatic bacteriuria. An-
tibiotics had uncertain effects on the subsequent occurrence of
symptomatic UTI (Analysis 1.1 (2 studies, 200 participants): RR
0.86, 95%CI 0.51 to 1.45; I2 = 0%). Origuen 2016 distinguished
pyelonephritis from symptomatic UTI and found no little or no
difference between the ones who were treated for asymptomatic
bacteriuria and those who were not (1 study, 112 participants: RD
-0.01, 95% CI -0.12 to 0.10).
Antimicrobial resistance
Origuen 2016 assessed the incidence of antimicrobial resistance
as the number of study participants in whom bacteria with ac-
quired non-susceptibility to at least one agent in three or more
antimicrobial categories were isolated during follow up. Samples
could be collected both in case of symptoms of UTI or as part
of routine screening. Even if numerically more people had a mul-
tidrug-resistant bacteria in the treatment group as compared with
the group not treated for asymptomatic bacteriuria (13/53 versus
12/59), the results were very uncertain (1 study, 112 participants:
RR 1.21, 95% CI 0.60 to 2.41).
Secondary outcomes
All-cause mortality, graft loss, (mostly) biopsy-proven acute rejec-
tion, and hospitalisation for UTI were only reported by Origuen
2016. In the group not treated for asymptomatic bacteriuria, 1 of
the 59 participants died (1.7%), graft loss occurred in 1/59 partic-
ipants (1.7%) and acute rejection in 12/59 participants (20.3%).
There was hospitalisation for UTI in 3 of the 59 untreated partici-
pants (5.1%). Overall the investigators reported little or no differ-
ence between the two groups for any of these outcomes (Analysis
1.3).
Graft function
Both included studies assessed the effect of antibiotics on graft
function. Antibiotics had uncertain effects on graft function, as
measured by SCr (Analysis 1.4 (2 studies, 200 participants): MD
-0.08 mg/dL, 95% CI -0.35 to 0.18; I2 = 70%).
Also, there was no significant effect of antibiotics on change in
graft function from baseline to end of study. In Moradi 2005,
mean plasma creatinine concentrations rose during the study pe-
riod from 1.16 ± 0.27 mg/dL to 1.2 ± 0.55 mg/dL in the antibi-
otics group versus 1.42 ± 0.67 mg/dL to 1.43 ± 0.56 mg/dL in
the no treatment group. In Origuen 2016, mean change in eGFR
from baseline to end of study was 0.53 ± 7.6 mL/min/1.73 m
2 in the antibiotics group (data available for 26/53 participants,
49.1%), as compared with 0.11 ± 15.8 mL/min/1.73 m2 in the
untreated group (data available for 37/59 participants, 62.7%)
Persistence or relapse of asymptomatic bacteriuria
Both studies noted high frequencies of persisting asymptomatic
bacteriuria in both groups.
InMoradi 2005, bacteriuria recurred in 25/43 treated participants
(58.1%) and 33/45 untreated participants (73.3%). The differ-
ence was not statistically significant (RD -0.15, 95% CI -0.33 to
0.05). Of note, the authors did not provide a specific definition
of the term “recurrence”. Attempts to contact the corresponding
author were unsuccessful.
In Origuen 2016, investigators took a sample for urinalysis in
the patients treated with antibiotics, two weeks after completing
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the treatment. Analysis of data obtained from 90% of the par-
ticipants revealed that persisting asymptomatic bacteriuria (as de-
fined in our systematic review) was common despite the use of
antibiotics, occurring in 46/131 episodes (35.1%). In addition,
a different uropathogen was cultured in 18 episodes (13.7%). As
a consequence, microbiological cure was achieved in 51.1% (67/
131) of the episodes treated with antibiotics. In the control group,
no systematic urinalysis occurred at two weeks, but subsequent
cultures were used to evaluate the outcome. Under these condi-
tions, asymptomatic bacteriuria persisted after 59% (175/296) of
the untreated episodes, and more frequently in the control group
(RD -0.24, 95% CI -0.33 to -0.14).
Adverse reactions to antimicrobial agents
Only Origuen 2016 assessed incidence of adverse reactions to an-
timicrobial agents. The investigators did not compare the inci-
dence of adverse events between the two study groups. However,
there was no severe adverse event attributable to the use of an-
tibiotics and non-severe adverse events appeared to be rare (two
patients experienced mild diarrhoea in relation with a course of
amoxicillin-clavulanate and one patient experienced nausea).
Other outcomes
Additionally, one study evaluated incidence of C. difficile-asso-
ciated diarrhoea (Origuen 2016). In this study, C. difficile-asso-
ciated diarrhoea occurred in 3/53 participants from the antibi-
otics group (5.7%) and 5/59 participants from the control group
(8.5%). There was no statistically significant difference between
the two groups (RD -0.03, 95% CI -0.13 to 0.08).
D I S C U S S I O N
Summary of main results
Based on two studies treating kidney transplant recipients with
asymptomatic bacteriuria had uncertain effects on preventing
symptomatic UTI, and entailed uncertain risks for selecting re-
sistant strains. Persistence of asymptomatic bacteriuria was high
regardless of treatment and although the available data were lim-
ited, so far, there is no evidence to suggest antibiotic treatment of
asymptomatic bacteriuria would improve patient and graft out-
comes such as all-cause mortality, graft loss, acute rejection, hos-
pitalisation for UTI or graft function. Data on adverse reactions
were very limited, but there seemed to have been no severe adverse
event attributable to the antibiotic treatment, and non-severe ad-
verse events appeared to be rare.
Overall completeness and applicability of
evidence
The two studies contributing to this review included both male
and female adult kidney transplant recipients.
As kidney transplant recipients with asymptomatic bacteriuria
in the first few months after transplantation (> two months in
Origuen 2016, > one year in Moradi 2005) were not included in
these studies, the applicability of our findings to the early post-
transplant phase is unclear. First, these exclusions may reflect the
belief that asymptomatic bacteriuria increases susceptibility to sub-
sequent UTI specifically in the first few months after transplanta-
tion due to the degree of immunosuppression, urologic manipula-
tions and mucosal bleeding, compelling physicians to start antibi-
otics even when kidney transplant recipients are asymptomatic.
Second, establishing the diagnosis of UTI may be difficult early
after transplantation, with typical signs and symptoms of UTI be-
ing both common and often due to non-infectious causes. Third,
the incidence of asymptomatic bacteriuria and UTI is highest in
the first months after transplantation (Parasuraman 2013). De-
spite these specificities, the usefulness of screening for and treating
asymptomatic bacteriuria in the early post-transplant period have
not been evaluated in a RCT and this should be subject to further
study.
We need to be careful when extrapolating the results of this
review to patients with ureteral stents or indwelling urethral
catheters, as the two included studies excluded these patients.
People with urinary devices develop symptomatic UTI more fre-
quently than non-catheterized people in the general population
(Hooton 2010). The use of such devices is associated with biofilm
formation, where asymptomatic bacteriuria is universal and per-
sistent (Nicolle 2014b). While screening for and treatment of
catheter associated-asymptomatic bacteriuria is not recommended
in the general population, very little is known about what to do
in kidney transplant recipients with urinary devices.
Because both studies exclusively enrolled kidney transplant recip-
ients, caution is required when managing people with combined
transplants (e.g. kidney and pancreas). Even if very little is known
on the effect of asymptomatic bacteriuria in combined transplant
recipients, there is no reason to assume antimicrobial agents would
be more effective for asymptomatic bacteriuria in these patients,
as compared with kidney transplant recipients. To the best of our
knowledge, there is no evidence to support strategies of screen-
ing for and treatment of asymptomatic bacteriuria in recipients of
non-kidney organ transplants (Parasuraman 2013).
Last, Origuen 2016 excluded pregnant patients. Screening for and
treatment of asymptomatic bacteriuria have historically been con-
sidered to effectively reduce the risk of pyelonephritis in themother
and possibly complications in the child (Smaill 2015). Even if
this approach has recently been questioned (Kazemier 2015), our
systematic review does not provide any additional information as
pregnant women were excluded from the review.
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Quality of the evidence
First, the estimates of the effect of antibiotics for preventing symp-
tomatic UTI were very imprecise, and consistent with either im-
portant benefits or harms (Analysis 1.1 (2 studies, 200 partici-
pants): RR 0.86, 95% CI 0.51 to 1.45; I2= 0%). Regarding the
absence of significant difference between study groups, we esti-
mated that these two studies lacked power to detect a potential
effect of antibiotics for preventing symptomatic UTI. In fact, nei-
ther study had an adequate sample size calculation. No sample
size calculation was reported in Moradi 2005. In Origuen 2016, a
sample size calculation was conducted based on the assumption of
a risk reduction of pyelonephritis from 23% in the control group
to 3% in the antibiotics group. Under these conditions, the study
investigators estimated that 55 patients per arm were required to
have a 90% chance of detecting the risk reduction expected be-
tween study groups, as significant at the 5% level. However, the
incidence of pyelonephritis was much lower in the control group
than expected (8.4% versus 23%) and we estimated that the sam-
ple size calculation was based on an overly optimistic effect of an-
timicrobial agents.
Secondly, the included studieswere at high risk of bias fromvarious
sources. Regrettably, neither of the included studies attempted
to blind participants, personnel or data analysts. As symptoms
of UTI are partly subjective, we anticipated this would put the
results at risk of being biased in favour of antibiotic treatment. As
a consequence however, chances are slim that blinding would have
been associatedwith greater effect of antibiotics on the incidence of
symptomaticUTI.Nonetheless, the studieswere also considered at
high risk of attrition bias (Moradi 2005; Origuen 2016), selection
bias, and reporting bias (Moradi 2005).
These limitations suggest that additional studies are likely to
change our confidence in the effect estimates (GRADE 2008).
Potential biases in the review process
Although this review was conducted by two or more independent
authors, used a comprehensive search of the published and un-
published research designed by a specialist librarian, and examined
all potentially relevant clinical outcomes, potential biases exist in
the review process. The single most important reservation is that
four authors of this systematic review are involved in an investi-
gator-led multicentre ongoing RCT comparing antibiotics versus
no treatment for asymptomatic bacteriuria in kidney transplant
recipients (BiRT Study 2013). No results were available at the
time this systematic review was written, and as a consequence no
results were included in this review. None of the authors have any
commercial conflict of interest related to this review, and although
every care was taken to interpret the data as objective as possible,
it is difficult to rule out a subconscious intellectual conflict that
may have influenced the conclusions.
Agreements and disagreements with other
studies or reviews
To the best of our knowledge, there has been no previous attempt
to specifically and systematically review the evidence for treating
asymptomatic bacteriuria in kidney transplant recipients with an-
tibiotics. In 2005, the IDSA guidelines for the diagnosis and treat-
ment of asymptomatic bacteriuria in adults refrained from mak-
ing a recommendation in kidney transplant recipients for want of
evidence (Nicolle 2005). In 2013, the American Society of Trans-
plantation Infectious Diseases Community of Practice suggested
not treating asymptomatic bacteriuria that occurs beyond three
months after kidney transplantation, unless in case of an accom-
panying rise in SCr concentration (Parasuraman 2013). However,
this recommendation was not based on a systematic review but on
expert opinion, and this group of expert acknowledged that such
a strategy may be too aggressive and lead to emergence of antimi-
crobial resistance. Based on the evidence currently available, our
review do not support treating asymptomatic bacteriuria before or
after three months post-transplantation.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on currently available data, there is insufficient evidence to
support routinely treating kidney transplant recipients with an-
tibiotics in case of asymptomatic bacteriuria after transplantation,
but data are scarce. Because the usefulness of antibiotics has not
been demonstrated in kidney transplant recipients with asymp-
tomatic bacteriuria, it is not clear whether a strategy of screening
for asymptomatic bacteriuria with urine cultures should be per-
formed. Screening cultures could provide information on the level
of antimicrobial resistance in case of asymptomatic bacteriuria,
but the effect of such findings regarding the choice of empirical
therapy in case of subsequent symptomatic UTI has to be deter-
mined.
Implications for research
Further studies assessing routine antibiotic treatment would in-
form practice and we eagerly await the results of three ongoing
randomised studies, which may help resolve existing uncertain-
ties. Our review is limited by the lack of information on baseline
level of antimicrobial resistance and the effect of antibiotics given
for asymptomatic bacteriuria after transplantation on the risk of
promoting antimicrobial resistance, both in the urine and in the
gut, which is the reservoir of resistant organisms. We would urge
future research to include information on both baseline level of
antimicrobial resistance and change in drug resistance after an-
tibiotic treatment, using appropriate samples (e.g. rectal swab and
urine specimens) and systematic methodology.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Moradi 2005
Methods • Study design: parallel quasi-RCT
• Recruitment period: March 2002 to February 2003
• Duration of follow-up: 9 to 12 months
Participants • Country: Iran
• Setting: Single centre
• Inclusion criteria: men and women kidney transplant recipients ≥ 18 years with a
diagnosis of asymptomatic bacteriuria (defined as the as the joint presence of pyuria
and bacteriuria in urine analysis, with a positive culture with colony count > 100,000
of one organism and the absence of irritative voiding symptoms, fever and chills); at
least one year post-transplantation
◦ Main causes of underlying disease: hypertension (43.1%), diabetes mellitus
(14.8%), glomerulonephritis (12.5%), urolithiasis (10.2%)
• Number (randomised/analysed): 100/88 (12 excluded after randomisation)
◦ Treatment group (43); control group (45)
• Sex (M/F): treatment group (20/23); control group (20/25)
• Mean age ± SD (years): treatment group (44.2 ± 12.7); control group (40.9 ± 13.
2)
• Exclusion criteria: urethral catheter; ureteral stent; Proteus infection
Interventions Treatment group
• Antibiotic: choice of antibiotics was according to the antimicrobial susceptibility
testing results
◦ Duration of therapy: 10 days
◦ Doses: not provided
• In case of recurrence of asymptomatic bacteriuria during the follow-up period,
treatment was repeated in the intervention arm
Control group
• No treatment
Outcomes • Incidence of symptomatic UTI
• Graft function as measured by SCr during the follow-up period
• Incidence of relapse or persistent asymptomatic bacteriuria
Notes • No specific strategy mentioned to obtain good quality urine samples
• Primary outcome not defined
• Funding source: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Moradi 2005 (Continued)
Random sequence generation (selection
bias)
High risk Quote: ”According to the order of patients’
transplant code, they were divided into two
groups of case and control, in every other
one manner“
Comment: high-risk of selection bias is as-
sociated with quasi-RCTs
Allocation concealment (selection bias) High risk Quote: ”According to the order of patients’
transplant code, they were divided into two
groups of case and control, in every other
one manner“
Comment: high-risk of selection bias is as-
sociated with quasi-RCTs
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: ”In case group, a 10-day oral antibi-
otic therapy was administered (...). The pa-
tients in control group were left untreated“
Comment: as symptoms ofUTIs are in part
subjective, the absence of blinding may im-
pact the number of symptomatic infections
observed
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: ”In case group, a 10-day oral antibi-
otic therapy was administered (...). The pa-
tients in control group were left untreated“
Comment: as symptoms of urinary tract
infections are in part subjective, the ab-
sence of blinding may impact the number
of symptomatic infections observed
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: ”The patients with lost follow-up
visits, acute rejection, and pyelonephritis
leading to hospitalization during the study
were excluded. (...) Twelve patients were
excluded of the study, 11 because of lost
follow-up visits and 1 because of acute
pyelonephritis, and eventually, data from
88 patients were analyzed“
Comment: Twelve enrolled patients (12%)
were excluded from the analysis (11 sub-
jects lost to follow-up and 1 patient due to
occurrence of acute graft pyelonephritis). A
high-risk of attrition bias was suspected
Selective reporting (reporting bias) High risk Comment: no published protocol. Authors
did not divided outcomes into primary
and secondary outcomes. Some expected
outcomes such as incidences of antimicro-
bial resistance, pyelonephritis, graft rejec-
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Moradi 2005 (Continued)
tion and graft loss, all-cause mortality, inci-
dence of hospitalisation for UTI and inci-
dence of adverse reactions to antimicrobial
agents were not reported
Other bias High risk Comment: Moradi 2005 did not provide
a specific definition of the term ”symp-
tomatic UTI“ and there were no details
on the episodes of symptomatic UTI. At-
tempts to contact the corresponding author
were unsuccessful
Origuen 2016
Methods • Design: parallel RCT
• Recruitment period: April 2011 to February 2014
• Duration of follow-up : the follow-up period was theoretically extended to the
first 2 years after transplantation unless acute pyelonephritis (9 patients), graft loss (2
patients) or death (3 patients) occurred during the study period. Median follow-up
time was 16.9 months (range 0.4 to 22), with 61/112 (54.5%) patients completing the
follow-up until two years after transplantation
Participants • Country: Spain
• Setting: single centre
• Inclusion criteria: men and women kidney transplant recipients ≥ 18 years with a
diagnosis of asymptomatic bacteriuria according to IDSA guidelines; at least two
months post-transplantation; both inpatients and outpatients were potentially eligible
◦ Main causes of underlying disease: diabetes mellitus (23.2%),
glomerulonephritis (21.4%), polycystic kidney disease (14.3%), hypertension (9.8%)
• Number: treatment group (53); control group (59) patients
• Mean age ± SD (years): treatment group (55.4 ± 14.5); control group (53.04 ±
15.8)
• Sex (M/F): treatment group (28/25); control group (31/28)
• Exclusion criteria: kidney-pancreas transplant recipients; double J ureteral stents
or indwelling urethral catheter; pregnancy; graft loss within the first two months after
transplantation; occurrence of at least one episode of asymptomatic bacteriuria
between the end of the second month after transplantation and the study screening
Interventions Treatment group
• Antibiotics: choice of antibiotics: according to the antimicrobial susceptibility
testing results
◦ Duration of therapy: 3 to 7 days for the first episode of asymptomatic
bacteriuria. The first relapse was theoretically treated for 14 days. In presence of two or
more relapses, a urinary tract ultrasound examination was ordered to rule out
obstruction, and a 6-week antibiotic course was prescribed. If a further relapse was
detected, a long-term suppressive therapy with low doses of antibiotic was set up for 6
months
◦ Doses: more than 10 different antimicrobial agents were used during this
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Origuen 2016 (Continued)
study, with choice and dosing selected according to parameters such as antimicrobial
susceptibility testing results
• In case of recurrence of asymptomatic bacteriuria during the follow-up period,
treatment was repeated in the intervention arm
Control group
• No treatment
Outcomes Primary outcome
• Cumulative incidence of a first episode of acute pyelonephritis, as defined by the
simultaneous presence of fever and bacteriuria and/or bloodstream infection along with
at least one of the following symptoms: lumbar pain, graft pain, chills and/or irritative
voiding symptoms
Secondary outcomes
• Incidence of lower UTI
• Incidence of overall symptomatic UTI
• Incidence of colonization or infection due to multi-drug resistant bacteria, with
multi-drug resistance being defined as acquired non-susceptibility to at least one agent
in three or more antimicrobial categories
• Graft function as measured by eGFR at 12 and 24 months after transplant
(MDRD equation)
• Incidence of graft loss, including permanent return to dialysis or retransplant
(does not include death with a functioning graft)
• Incidence of acute graft rejection (biopsy-proven or not)
• Incidence of adverse events
• Incidence of persistent asymptomatic bacteriuria
• Incidence of Clostridium difficile, defined as the passage of 3 or more unformed
stools in 24 hours in the presence of a positive stool test for toxigenic C. difficile
• Incidence of hospital admission for UTI
• Incidence of all-cause mortality
Notes • Specific strategies to obtain good quality urine samples: dedicated nurses
instructed the patients in the proper collection of urinary samples to minimize the risk
of contamination. In case of contamination of the culture, urine collection was repeated
• Funding source: “This work was partially supported by the Fundacion Mutua
Madrile~na de Investigacion Medica (FMM Grant 2010/0015), by the Spanish
Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (Fondo de
Investigaciones Sanitarias [FIS] 12/02269 and Proyecto Integrado de Excelencia [PIE]
13/00045), and by the European Development Regional Fund (EDRF) “A way to
achieve Europe”.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “participants were randomised (1:
1 ratio) using a predetermined com-
puter-generated sequence and consecu-
tively numbered sealed envelopes”
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Origuen 2016 (Continued)
Allocation concealment (selection bias) Low risk Quote: “participants were randomised (1:
1 ratio) using a predetermined com-
puter-generated sequence and consecu-
tively numbered sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label, parallel-group, ran-
domised trial”
Comment: as symptoms ofUTIs are in part
subjective, the absence of blinding may im-
pact the number of symptomatic infections
observed
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label, parallel-group, ran-
domised trial”
Comment: as symptoms ofUTIs are in part
subjective, the absence of blinding may im-
pact the number of symptomatic infections
observed
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “the 12- and 24-month follow-up
periods were completed in 98 (86.6%) and
61 patients (54.4%), respectively”
Comment: all the 112 participants were in-
cluded into the intention-to-treat analysis.
However, little more than half reached the
end of the two year study period. Partici-
pants were withdrawn after they developed
acute pyelonephritis, which could have bi-
ased results for the other outcomes
Selective reporting (reporting bias) Low risk Comment: all the expected outcomes were
reported.
Other bias Low risk Quote: ’this work was partially supported
by the Fundacio n Mutua Madrilen a
de Investigacio n Me dica (FMM Grant
2010/0015), by the Spanish Ministry of
Economy and Competitiveness, Instituto
de Salud Carlos III (Fondo de Investi-
gaciones Sanitarias [FIS] 12/02269 and
Proyecto Integrado de Excelencia [PIE] 13/
00045), and by the European Develop-
ment Regional Fund (EDRF) “A way to
achieve Europe”. J.O. holds a research-
training contract “Rio Hortega” (CM13/
00180) from the SpanishMinistry of Econ-
omy and Competitiveness (Instituto de
Salud Carlos III). M.F.R. holds a clinical
research contract “Juan Rode s” (JR14/
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Origuen 2016 (Continued)
00036) from the SpanishMinistry of Econ-
omy and Competitiveness, Instituto de
Salud Carlos III“
Comment: a low-risk of sponsorship bias is
expected due to the nature of the study
IDSA - Infectious Diseases Society of America; MDRD -Modification of Diet in Renal Disease; M/F - male/female; RCT - randomised
controlled trial; SD - standard deviation; UTI - urinary tract infection
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Castelao 1993 Wrong population: evaluated the role of perioperative antibiotic prophylaxis
Cohen 1988 Wrong population: evaluated the role of perioperative antibiotic prophylaxis
Ferreira 1990 Wrong population: evaluated the role of perioperative antibiotic prophylaxis
Fox 1990 Wrong population: evaluated the effect of long-term prophylaxis with cotrimoxazole following kidney trans-
plantation
Hall 1974 Wrong population: evaluated the risk of leucopenia associated with the use of cotrimoxazole in kidney transplant
recipients having UTI
Hibberd 1992 Wrong population: compared two different regimen of long-term antibiotic prophylaxis following kidney
transplantation
Khosroshahi 2006 Wrong population: compared various doses of prophylaxis with cotrimoxazole following kidney transplantation
Maddux 1989 Wrong population: evaluated the effect of antibiotics prophylaxis following kidney transplantation
Matteucci 1998 Wrong population: evaluated the effect of perioperative antibiotic prophylaxis
Melchor 1996 Wrong population: evaluated the effect of a 10-days antimicrobial prophylaxis following kidney transplantation
Moyses-Neto 1997 Wrong population: evaluated the effect of long-term prophylaxis with ciprofloxacin following kidney trans-
plantation
NCT01820897 Wrong population: compares two regimen of long-term prophylaxis following kidney transplantation
Robles 1990 Wrong population: evaluated the role of perioperative antibiotic prophylaxis
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(Continued)
Salehipour 2010 Wrong population: evaluated the effect of intravesical administration of antibiotics at the time of transplantation
Salmela 1990 Wrong population: evaluated the effect of intravesical administration of antibiotics just before transplantation
Tegzess 1986 Wrong population: evaluated different regimen of postoperative short-term antibiotics prophylaxis
Tolkoff 1982 Wrong population: evaluated the effect of long-term prophylaxis with cotrimoxazole following kidney trans-
plantation
Townsend 1980 Wrong population: evaluated the role of perioperative antibiotic prophylaxis
Wilms 1986 Wrong population: evaluated the effect of antibiotic prophylaxis in kidney transplant recipients
UTI - urinary tract infection
Characteristics of ongoing studies [ordered by study ID]
BiRT Study 2013
Trial name or title The Bacteriuria in Renal Transplantation (BiRT) study: a prospective, randomised, parallel-group, multicen-
ter, open-label, superiority trial comparing antibiotics versus no treatment in the prevention of symptomatic
urinary tract infection in kidney transplant recipients with asymptomatic bacteriuria
Methods • Study design: parallel RCT
• Duration of follow-up: 12 months
• Power calculation: performed (sample size calculation: 198 patients)
• Blinding: open-label
Participants • Countries: Belgium, France
• Setting: multicentre
Inclusion criteria
• Kidney transplant recipient with asymptomatic bacteriuria, defined as the isolation of a single bacterial
species in a quantitative count ≥ 100.000 CFU/mL in a single collected urine specimen from a patient
without biological or clinical signs or symptoms referable to UTI
• Sex: both
• Age : ≥ 18 years
• Time from transplantation: from the end of the 2nd month post-transplantation
• Other: in-patients and out-patients are included
Exclusion criteria
• Pregnant women or women who wish to become pregnant during the course of the study
• Presence of indwelling urinary devices such as urethral catheter, ureteral catheter, nephrostomy and/or
suprapubic catheter
• Combined transplantation (liver-kidney, lung-kidney, heart-kidney)
• Urinary tract surgery during the last two months
• Surgical urological procedure planned in the next two weeks
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BiRT Study 2013 (Continued)
• Neutropenia (≤ 500 neutrophils/mm3)
• Important intensification of immunosuppression (Solumedrol bolus and/or use of thymoglobulin) or
any other treatment of an acute graft rejection in the last 2 months
• Use of antibiotics at the time of the asymptomatic bacteriuria (except for prevention of Pneumocystis
jirovecii)
• ESKD requiring dialysis
• Non-functioning native bladder (e.g. bladder dysfunction requiring intermittent self-catheterization,
orthotopic ileal neobladder)
• Recurrent acute graft pyelonephritis (≥ 2 episodes in the last year)
• Kidney transplant recipients who could not return for regular follow-up
Interventions Treatment group
• Antibiotics: choice of antibiotics started and selected according to the antibiogram results
• Duration of therapy: 10 days
• Doses: according to national recommendations
• In case of recurrence of asymptomatic bacteriuria during the follow-up period, treatment repeated in
the intervention arm
Control arm
• No antibiotics delivered in case of asymptomatic bacteriuria
Outcomes Primary outcome
• Cumulative incidence of a first episode of symptomatic UTI (time frame: 12 months)
Secondary outcomes (to be evaluated during the 12 months of follow-up)
• Incidence of a first episode of pyelonephritis
• Incidence of urinary source bacteraemia
• Proportion of patients with clearance of asymptomatic bacteriuria
• Occurrence of new episodes of asymptomatic bacteriuria
• Graft function (eGFR) and graft survival
• Biopsy-proven graft rejection
• Patient survival
• Level of antimicrobial resistance. Investigators will compare resistance profiles as an outcome for both
symptomatic urinary tract infection and asymptomatic bacteriuria. Investigators will evaluate both the rate
of multidrug resistant (with multidrug-resistance being defined as non-susceptibility to at least one agent in
three or more antimicrobial categories) and resistance to the antibiotic given for the treatment of
asymptomatic bacteriuria (in the “antibiotics” arm)
• Total number of days of antimicrobial therapy
• Cost of antimicrobial treatment for asymptomatic bacteriuria and symptomatic UTI
• Number of hospitalizations for asymptomatic bacteriuria and symptomatic UTI treatment
• Incidence of Clostridium difficile-associated diarrhoea
• Total number of symptomatic UTIs
• Within-person reproducibility of urinanalysis results (at baseline)
Specific strategies to obtain good quality urine samples
• Diagnosis of asymptomatic bacteriuria based on results of culture of a urine specimen collected in a
manner that minimizes contamination. Even in women, a second urine collection is not necessary for
inclusion in the study, but is highly recommended
• Samples with increased number of epithelial cells should encourage physicians to control the urine
analysis
• Analysis of urine samples performed within two hours following the collection in order to minimize
ex-vivo bacterial multiplication and leukocytes lysis
26Antibiotics for asymptomatic bacteriuria in kidney transplant recipients (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
BiRT Study 2013 (Continued)
• Rules such as the need for clean catch midstream urine samples regularly recalled to the kidney
transplant recipient
Starting date April 2014
Contact information Julien Coussement, MD (co-ordinating investigator)
Dept. of Nephrology, Dialysis and Kidney Transplantation, Hôpital Erasme - Université Libre de Bruxelles
Route de Lennik, 808, 1070 Brussels, Belgium.
Phone: +32.2.555.30.49 / Fax: + 32.2.555.64.99 / E-mail: jcoussem@ulb.ac.be
Notes Protocol published by The Lancet (reference: 14PRT/5447): http://www.thelancet.com/protocol-reviews/
14PRT-5447
NCT01771432
Trial name or title Antibiotic treatment versus no therapy in kidney transplant recipients with asymptomatic bacteriuria. A
prospective randomised study (BAC01)
Methods • Study design: parallel RCT
• Duration of follow-up: 1st year after transplantation
• Power calculation: yes (sample size calculation: 200 patients)
• Blinding: open-label
Participants • Country: Spain
• Setting: multicentre
Inclusion criteria
• Patients who receive a transplant allograft during study period
• Sex: both
• Age: 18 to 85 years
• Time from transplantation: unknown
Exclusion criteria
• No acceptation of study
Interventions Treatment arm
• Antibiotics
Control arm
• No therapy
Outcomes Primary outcome
• Incidence of pyelonephritis
Secondary outcomes
• Kidney function
• Need for hospitalisation
• Incidence of graft loss
• Mortality
• Infection by multiresistant microorganisms
Specific strategies to obtain good quality urine samples: not specified
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NCT01771432 (Continued)
Starting date January 2013
Contact information Núria Sabé Fernàndez
Hospital Universitari de Bellvitge
L’Hospitalet de Llobregat, Barcelona, Spain, 08907
Phone number: +34932607625
E-mail: nfsabe@bellvitgehsopital.cat
Notes Estimated study completion date: December 2015
NCT02113774
Trial name or title The impact of antimicrobial treatment for asymptomatic bacteriuria in renal transplant patients
Methods • No details available (authors contacted)
Participants • Country: Israel
• Location: single centre
Inclusion criteria
• Kidney transplant recipients with a positive urine culture defined as ≥ 105 CFU/mL of a known single
pathogen
• Sex : both
• Age: ≥ 18 years
• Time from transplantation: ≥1 month and ≤ 12 months after kidney transplantation
Exclusion criteria
• Any one of the following signs and symptoms: fever, abdominal pain, dysuria, frequency, urgency,
flank pain, costovertebral-angel tenderness or tenderness over the transplanted kidney
• Active infections in another site
• Leucocytosis (WBC > 18,000/µL) or leucopenia (WBC < 3,000 /µL)
• Elevation of SCr > 15% of its baseline level
• Obstructive or other urological complications following transplantation as known foreign device
(stent/double-J-Cath, any catheter) in the urinary tract system, known obstruction of the transplanted
kidney, indwelling or intermittent catheterization
• Pregnant or lactating women
• Candidates to invasive urologic procedures
• Inability to return for regular follow-up
• Previous enrolment in this study
• Patients unable to give informed consent
Interventions Treatment group
• Antimicrobial treatment according to in-vitro susceptibility
Control group
• No therapy
Outcomes Primary outcome
• Symptomatic UTI (at 30 days)
Secondary outcomes
• 25% reduction in eGFR (at 1 year)
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NCT02113774 (Continued)
• Graft loss (at 1 year)
Specific strategies to obtain good quality urine samples: not specified
Starting date April 2014
Contact information Ruth Rahamimov
Head of Transplant investigator service
Rabin Medical centre, Israel
Notes
CFU - colony forming units; ESKD - end-stage kidney disease; eGFR - estimated glomerular filtration rate; RCT - randomised
controlled trial; SCr - serum creatinine; UTI - urinary tract infection; WBC - white blood cells
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D A T A A N D A N A L Y S E S
Comparison 1. Antibiotics versus no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic urinary tract
infection
2 200 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.51, 1.45]
2 Antimicrobial resistance 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Secondary dichotomous
outcomes
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 All-cause mortality 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Graft loss 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 Acute rejection 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 Hospitalisation for UTI 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Graft function (creatinine at end
of study)
2 200 Mean Difference (IV, Random, 95% CI) -0.08 [-0.35, 0.18]
C O N T R I B U T I O N S O F A U T H O R S
1. Draft the protocol: JC, AS, DA, EVN, AW
2. Study selection: JC, AS, EVN
3. Extract data from studies: JC, AS,
4. Enter data into RevMan: JC, AS
5. Carry out the analysis: JC, AS, EVN
6. Interpret the analysis: JC, AS, DA, EVN, AW
7. Draft the final review: JC, AS, DA, EVN, AW
8. Disagreement resolution: EVN
9. Update the review: JC
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D E C L A R A T I O N S O F I N T E R E S T
• Julien Coussement: is the coordinating investigator of a multicentre RCT comparing antibiotics versus no treatment in the
prevention of symptomatic UTI in kidney transplant recipients with asymptomatic bacteriuria (BiRT Study 2013). This study was
registered on Clinicaltrials.gov in May 2013 and started recruiting in April 2014. Results of this study are expected to become
available from 2019. Julien Coussement received two grants from not-for-profit organisations for the purpose of initiating the study
(David & Alice Van Buuren Research Grant 2014 & Prix 2014 du Fonds Carine Vyghen).
• Anne Scemla: is an investigator of a multicentre RCT comparing antibiotics versus no treatment in the prevention of
symptomatic UTI in kidney transplant recipients with asymptomatic bacteriuria (BiRT Study 2013). This study was registered on
Clinicaltrials.gov in May 2013 and started recruiting in April 2014. Results of this study are expected to become available from 2019.
• Daniel Abramowicz: is an investigator of a multicentre RCT comparing antibiotics versus no treatment in the prevention of
symptomatic UTI in kidney transplant recipients with asymptomatic bacteriuria (BiRT Study 2013). This study was registered on
Clinicaltrials.gov in May 2013 and started recruiting in April 2014. Results of this study are expected to become available from 2019.
• Evi V Nagler: is an investigator of a multicentre RCT comparing antibiotics versus no treatment in the prevention of
symptomatic UTI in kidney transplant recipients with asymptomatic bacteriuria (BiRT Study 2013). This study was registered on
Clinicaltrials.gov in May 2013 and started recruiting in April 2014. Results of this study are expected to become available from 2019.
• Angela C Webster: None known
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Following the 2005 IDSA guidelines (Nicolle 2005), we included an additional asymptomatic bacteriuria definition to be applied to
catheterized patients. The following sentence was added: ”a single catheterized urine specimen with one bacterial species isolated in a
quantitative count ≥ 100 CFU/mL identifies bacteriuria in women or men“.
We modified the criteria to evaluate the effect of antibiotics on the incidence of antimicrobial resistance between protocol and review.
In hindsight, we considered the criteria we initially chose (incidence of bacteriuria resistant to primary antibiotic treatment) difficult
to assess in studies with groups of untreated patients. We therefore decided to evaluate antimicrobial resistance using a widely accepted
criterion that can easily be evaluated in both treated and untreated participants (isolation of a multidrug-resistant bacterium, with
multidrug-resistance being defined as non-susceptibility to at least one agent in three or more antimicrobial categories).
The following definitions have been added in the section entitled ”secondary outcomes“:
Relapsing and persistent asymptomatic bacteriuria were defined as follows:
• Relapsing asymptomatic bacteriuria: recurrence of asymptomatic bacteriuria after clearance of the initial isolate
• Persistent asymptomatic bacteriuria: persistence of an organism similar to the initial isolate (same species with similar
antimicrobial-susceptibility profile).
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